Nice article! We've heard from leaders in dialysis that the incentive to use high-cost but effective therapies once they're in the bundle drops quickly to 0%...
Thanks for reading always, Rory! I've heard similar feedback. This has to be one of the more complex and nuanced topics I've written about to date. There isn't an obvious path ahead so far as I can tell. Caveat being I don't have all the data readily available, and I'm not too sure who does.
![Signals From [Space]](https://substackcdn.com/image/fetch/w_36,h_36,c_fill,f_webp,q_auto:good,fl_progressive:steep,g_auto/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa4736f49-6a20-4fd6-a3de-d48cb4b105f2_375x375.png)
![Signals From [Space]](https://substackcdn.com/image/fetch/e_trim:10:white/e_trim:10:transparent/h_72,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F2efc1ef1-ba0b-4ca3-b9f6-a9a790da4b38_1344x256.png)
Nice article! We've heard from leaders in dialysis that the incentive to use high-cost but effective therapies once they're in the bundle drops quickly to 0%...
Thanks for reading always, Rory! I've heard similar feedback. This has to be one of the more complex and nuanced topics I've written about to date. There isn't an obvious path ahead so far as I can tell. Caveat being I don't have all the data readily available, and I'm not too sure who does.
We've talked to folks at CMMI and they seemed surprised and caught unprepared when we asked about this.